Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.48 |
| ▸ | TUBB | P07437 | 5/20 | 0.48 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.48 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.48 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.48 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.48 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.48 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.48 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.48 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.48 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.48 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.48 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.48 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.48 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.48 |
| ▸ | EGFR | P00533 | 3/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16183302 | 0.93 | MAPT (0.49) | GAAMAPTALDH1A1TUBB4ATUBB | |
| SCHEMBL16183298 | 0.93 | ALDH1A1 (0.49) | GAAMAPTALDH1A1TUBB4ATUBB | |
| SCHEMBL14474807 | 0.91 | GBA1 (0.49) | GAAMAPTALDH1A1CYP11B2CYP11B1 | |
| SCHEMBL14474806 | 0.91 | ALDH1A1 (0.43) | GAAMAPTALDH1A1TUBB4ATUBB | |
| SCHEMBL16183295 | 0.90 | TUBB4A (0.49) | GAAMAPTALDH1A1TUBB4ATUBB | |
| SCHEMBL14358632 | 0.90 | ABCG2 (0.55) | GAAMAPTALDH1A1TUBB4ATUBB | |
| Hydrochloric Acid SCHEMBL14358828 | 0.89 | ABCG2 (0.54) | GAAMAPTALDH1A1TUBB4ATUBB | |
| SCHEMBL14474643 | 0.89 | MAPT (0.49) | GAAMAPTALDH1A1TUBB4ATUBB | |
| SCHEMBL14358737 | 0.89 | MAPT (0.49) | GAAMAPTALDH1A1TUBB4ATUBB | |
| SCHEMBL14726317 | 0.89 | GAA (0.49) | GAAMAPTALDH1A1TUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-08-03 | — | — | US | disclosed |
| US-9630947-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-25 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | GALENEA CORPORATION | 2015-10-29 | — | — | US | disclosed |
| US-9073890-B2 | Therapeutic compounds and related methods of use | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307477-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | GAA 339/4885MAPT 519/4885ALDH1A1 2216/4885 |
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | GAA 1062/4885MAPT 417/4885ALDH1A1 2732/4885 |
| US-20170217923-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PTPRG, PPP2CA | GAA 339/4885MAPT 519/4885ALDH1A1 2216/4885 |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | GAA 406/4885MAPT 509/4885ALDH1A1 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.